TARIFFS LATEST US, China to slash tariffs for 90 days Milan - Delayed Quote • EUR Bristol-Myers Squibb Company (1BMY.MI) Follow Add holdings 41.15 -0.38 (-0.92%) As of 2:38:08 PM GMT+2. Market Open. All News Press Releases SEC Filings Trump’s Vow to Cut US Drug Prices Drags Pharma Stocks Lower (Bloomberg) -- President Donald Trump said he plans to order a cut in US prescription drug costs to bring them in line with other countries, spurring a drop in pharmaceutical shares worldwide.Most Read from BloombergA New Central Park Amenity, Tailored to Its East Harlem NeighborsAs Trump Reshapes Housing Policy, Renters Face Rollback of RightsWhat’s Behind the Rise in Serious Injuries on New York City’s Streets?Is Trump’s Plan to Reopen the Notorious Alcatraz Prison Realistic?NYC Warns of 17% D BMY Q1 Earnings Call: Growth Portfolio Offsets Declines, Guidance Raised Amid Pipeline Advancements Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported Q1 CY2025 results exceeding the market’s revenue expectations, but sales fell by 5.6% year on year to $11.2 billion. The company’s full-year revenue guidance of $46.3 billion at the midpoint came in 1.2% above analysts’ estimates. Its non-GAAP profit of $1.80 per share was 19.8% above analysts’ consensus estimates. Pharmaceutical Stocks Tumble on Trump Plan to Cut US Drug Prices (Bloomberg) -- Shares of pharmaceutical companies fell across the world after US President Donald Trump said he planned to order a cut in US prescription drug costs to bring them in line with other countries, prompting concern that profits will take a hit.Most Read from BloombergA New Central Park Amenity, Tailored to Its East Harlem NeighborsAs Trump Reshapes Housing Policy, Renters Face Rollback of RightsWhat’s Behind the Rise in Serious Injuries on New York City’s Streets?Is Trump’s Plan to R Bristol-Myers Squibb Company (BMY): One of the Best High-Yield Dividend Stocks for 2025 and Beyond We recently published a list of the 15 Best High-Yield Dividend Stocks for 2025 and Beyond. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other best high-yield dividend stocks. Over the years, dividend-paying stocks have become increasingly popular as investors lean toward income-focused investment strategies. Many […] Drug companies to pay Hawaii $700 million to settle Plavix blood thinner lawsuit Pharmaceutical companies have agreed to pay Hawaii $700 million to settle its lawsuit over the efficacy and safety of the blood thinner Plavix, the state attorney general's office announced Friday. A court ruling last year ordered Bristol Myers Squibb Company and three U.S.-based subsidiaries of French pharmaceutical company Sanofi to pay a combined $916 million. “Plavix has helped millions of people with cardiovascular disease around the world for nearly 30 years and it continues to be endorsed as a first-line therapy by leading treatment guidelines across the globe,” the statement added. 3 Healthcare Stocks in Hot Water Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 13.3%. This drawdown was worse than the S&P 500’s 5.8% fall. A Look at Pharma ETFs After Strong Q1 Earnings Many pharma bigwigs reported solid results, with some beating on earnings or revenues or both. Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. The Zacks Analyst Blog Highlights Verizon Communications, Bristol-Myers Squibb, Canadian Pacific and Nova LifeStyle Verizon Communications, Bristol-Myers Squibb, Canadian Pacific and Nova LifeStyle are part of the Zacks top Analyst Blog. Top Research Reports for Verizon Communications, Bristol-Myers Squibb & Canadian Pacific Today's Research Daily features new research reports on 16 major stocks, including Verizon Communications Inc. (VZ), Bristol-Myers Squibb Co. (BMY) and Canadian Pacific Kansas City Ltd. (CP), as well a micro-cap stock Nova LifeStyle, Inc. (NVFY). Improving Access to Care by Strengthening Local Health System Capacity NORTHAMPTON, MA / ACCESS Newswire / May 7, 2025 / By Catharine Grimes, President of the Bristol Myers Squibb Foundation We are in an era of unprecedented medical innovation. Scientists are making remarkable progress to diagnose and treat diseases, ... Bristol-Myers Squibb (NYSE:BMY) Appoints Cari Gallman As New General Counsel Bristol-Myers Squibb (NYSE:BMY) recently appointed Cari Gallman as the new Executive Vice President, General Counsel, and Chief Policy Officer following Sandra Leung’s retirement. This leadership change might have influenced investors' outlook on the company, contributing to a 3% increase in share price over the last week. However, this movement aligns with the overall market trend, which saw a rise of 2%. Moreover, broader market dynamics, including investor focus on impending Federal... Bristol Myers Squibb announces $40bn US investment plan over five years The funds will reportedly be allocated for R&D, technology advancements, and enhancing domestic manufacturing capacity. Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer PRINCETON, N.J., May 06, 2025--Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer Elanco (ELAN) Reports Q1: Everything You Need To Know Ahead Of Earnings Animal health company Elanco (NYSE:ELAN) will be reporting results tomorrow before market hours. Here’s what to look for. Bristol Myers to invest $40 billion in the US over 5 years The announcement of new investment was first made by CEO Christopher Boerner in an opinion piece published in Stat News on Monday, and was later confirmed to Reuters by a company spokesperson. In the Op-Ed, Boerner said the money will be spread across research and development, technology and domestic manufacturing, as U.S. drugmakers prepare to deal with Trump's tariffs. Trump has repeatedly threatened tariffs on pharmaceutical imports on national security grounds. Was Jim Cramer Right About Bristol-Myers Squibb Company (BMY)? We recently published a list of Did Jim Cramer Hit or Miss On These 13 Stock Predictions? In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other stocks that Jim Cramer discussed during the episode of Mad Money on May 1st, 2024. During the Mad Money episode […] Supernus Pharmaceuticals Earnings: What To Look For From SUPN Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be reporting earnings tomorrow after market close. Here’s what to look for. 1 Stock Under $50 with Solid Fundamentals and 2 to Keep Off Your Radar Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market. Jim Cramer Says He Likes Bristol-Myers Squibb (BMY) More Than Merck Due to Schizophrenia Drug We recently published a list of 10 Jim Cramer Stocks to Watch Amid Trump Tariff Wars. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other stocks that Jim Cramer discussed. Jim Cramer in a latest program on CNBC talked about the latest signs of de-escalation […] Performance Overview Trailing total returns as of 5/12/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) Return 1BMY.MI S&P 500 (^GSPC) YTD -24.23% -1.32% 1-Year +4.65% +11.13% 3-Year -9.07% +47.67%